Drug Profile
HIV DNA vaccine - ValiRx
Alternative Names: DNA-GTU vaccine; FIT-06; GTU MultiHIV; GTU-multi-HIV B clade DNA vaccine; GTU®-multiHIV B Clade VaccineLatest Information Update: 05 Apr 2021
Price :
$50
*
At a glance
- Originator FIT Biotech
- Developer European HIV Vaccine Alliance; FIT Biotech; Imperial College of Science, Technology and Medicine
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II HIV infections
Most Recent Events
- 05 Apr 2021 HIV DNA vaacine is still in phase I/II trial for HIV infections (Prevention) in Switzerland and United Kingdom (NCT02972450)
- 02 May 2019 ValiRx acquires global granted patents and intellectual property assets from FIT Biotech
- 28 Nov 2018 Phase-I/II clinical trials in HIV infections (Prevention) in Switzerland (IM) (NCT02972450)